Please login to the form below

Not currently logged in
Email:
Password:

decitabine

This page shows the latest decitabine news and features for those working in and with pharma, biotech and healthcare.

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

In May, the European Commission (EC) approved Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who can’t receive intensive chemotherapy. ... In the US, Venclyxto is

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient

  • Pharma deals during September 2013 Pharma deals during September 2013

    Astex' lead product is Dacogen (decitabine) for myelodysplastic syndromes (MDS). It was also recently approved for acute myeloid leukaemia (AML) in patients over 65 years of age in Europe.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...